NEW YORK (GenomeWeb) – CareDx reported after the close of the market on Wednesday that its third quarter revenues rose 74 percent year over year, thanks largely to a 6 percent increase in test volume for its AlloMap non-invasive blood test for heart transplant patients.

For the three months ended Sept. 30, the diagnostics company said revenues rose to $12.5 million from $7.2 million a year earlier, beating the average Wall Street analyst estimate of $11.5 million.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.